Known targets — ChEMBL curated mechanism
MTORPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5
The experimentally established mechanism targets of Bgt-226 Free Base. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR known ✓ | P42345 | 14/20 | 0.89 |
| ▸ | PIK3CA known ✓ | P42336 | 3/20 | 0.89 |
| ▸ | PIK3CD known ✓ | O00329 | 1/20 | 0.89 |
| ▸ | PIK3CB known ✓ | P42338 | 1/20 | 0.89 |
| ▸ | PIK3CG known ✓ | P48736 | 1/20 | 0.89 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.89 |
| ▸ | FECH | P22830 | 1/20 | 0.89 |
| ▸ | CLK1 | P49759 | 1/20 | 0.89 |
| ▸ | GSK3A | P49840 | 1/20 | 0.89 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.89 |
| ▸ | MELK | Q14680 | 1/20 | 0.89 |
| ▸ | MYLK3 | Q32MK0 | 1/20 | 0.89 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.89 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.89 |
| ▸ | TP53RK | Q96S44 | 1/20 | 0.89 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.81 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.81 |
| ▸ | RIOK2 | Q9BVS4 | 6/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | ATR | Q13535 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bgt-226 Free Base SCHEMBL29394351 | 1.00 | MTOR (0.89) | MTORPIK3CAPIK3CDCSNK2A2FECH | |
| Bgt-226 Free Base SCHEMBL31326455 | 1.00 | MTOR (0.89) | MTORPIK3CAPIK3CDCSNK2A2FECH | |
| Bgt-226 Free Base SCHEMBL996047 | 1.00 | MTOR (0.89) | MTORPIK3CAPIK3CDCSNK2A2FECH | |
| Bgt-226 Free Base SCHEMBL29388241 | 0.94 | MTOR (1.00) | MTORPIK3CAPIK3CDCSNK2A2FECH | |
| Bgt-226 Free Base SCHEMBL29388607 | 0.94 | MTOR (1.00) | MTORPIK3CAPIK3CDCSNK2A2FECH | |
| Bgt-226 Free Base SCHEMBL29351405 | 0.94 | MTOR (1.00) | MTORPIK3CAPIK3CDCSNK2A2FECH | |
| Bgt-226 Free Base SCHEMBL146939 | 0.94 | MTOR (1.00) | MTORPIK3CAPIK3CDCSNK2A2FECH | |
| Maleic Acid SCHEMBL993627 | 0.93 | MTOR (0.76) | MTORPIK3CAPIK3CDCSNK2A2FECH | |
| Fumaric Acid SCHEMBL993628 | 0.93 | MTOR (0.76) | MTORPIK3CAPIK3CDCSNK2A2FECH | |
| Fumaric Acid SCHEMBL993841 | 0.91 | MTOR (0.74) | MTORPIK3CAPIK3CDCSNK2A2FECH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 278 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3266455-B1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING MTOR INHIBITOR | KOREA ADVANCED INST SCI & TECH (KR) | 2020-12-30 | — | — | EP | claimed |
| US-20190070166-A1 | Optimized Method for Treating and Curing Arthritis, Diabetes, Multiple Sclerosis and Other Autoimmune Disease | POSTREL RICHARD (US) | 2019-03-07 | — | — | US | claimed |
| US-20160303137-A1 | DUAL PI3K AND WNT PATHWAY INHIBITION AS A TREATMENT FOR CANCER | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2016-10-20 | — | — | US | claimed |
| US-12037583-B2 | Compositions and methods for immunooncology | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| EP-3380620-B1 | OPTIMIZED LENTIVIRAL TRANSFER VECTORS AND USES THEREOF | NOVARTIS AG (CH) | 2024-07-03 | — | — | EP | disclosed |
| EP-4378957-A2 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1 | Novartis AG (CH) | 2024-06-05 | — | — | EP | disclosed |
| US-11999802-B2 | Compositions and methods for selective protein degradation | NOVARTIS AG (CH) | 2024-06-04 | — | — | US | disclosed |
| US-11999794-B2 | Human mesothelin chimeric antigen receptors and uses thereof | NOVARTIS AG (CH) | 2024-06-04 | — | — | US | disclosed |
| US-11981731-B2 | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-05-14 | — | — | US | disclosed |
| US-20240139244-A1 | CELLS EXPRESSING MULTIPLE CHIMERIC ANTIGEN RECEPTOR (CAR) MOLECULES AND USES THEREFORE | NOVARTIS AG (CH) | 2024-05-02 | — | — | US | disclosed |
| US-11970525-B2 | Treatment of cancer using GFR alpha-4 chimeric antigen receptor | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-04-30 | — | — | US | disclosed |
| US-20110251202-A1 | 1,3-Dihydro-imidazo[4,5-c]quinolin-2-ones as Lipid Kinase Inhibitors | NOVARTIS AG (CH) | 2011-10-13 | — | — | US | disclosed |
| US-7994170-B2 | 1,3-dihydro-imidazo[4,5-C]quinolin-2-ones as lipid kinase inhibitors | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | disclosed |
| EP-2292617-A1 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinase inhibitors | Novartis AG (CH) | 2011-03-09 | — | — | EP | disclosed |
| EP-2270008-A1 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinases inhibitors | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| US-20100056558-A1 | 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| US-7667039-B2 | 1,3-dihydro-imidazo [4,5-C] quinolin-2-ones as lipid kinase inhibitors | NOVARTIS AG (CH) | 2010-02-23 | — | — | US | disclosed |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1888578-A2 | IMIDAZOQUINOLINES AS LIPID KINASE INHIBITORS | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006122806-A2 | 1,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139244-A1 | CELLS EXPRESSING MULTIPLE CHIMERIC ANTIGEN RECEPTOR (CAR) MOLECULES AND USES THEREFORE | CD22, HAVCR2, CD47 | MTOR 4624/4885PIK3CA 3848/4885PIK3CD 3912/4885 |
| US-20100056558-A1 | 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | PDPK1, PI4KA, PIP4K2A | MTOR 89/4885PIK3CA 8/4885PIK3CD 9/4885 |
| US-11970525-B2 | Treatment of cancer using GFR alpha-4 chimeric antigen receptor | GFRA3, GFRA1, GFRA2 | MTOR 2741/4885PIK3CA 225/4885PIK3CD 375/4885 |
| US-11999794-B2 | Human mesothelin chimeric antigen receptors and uses thereof | HAVCR2, CD44, MUC1 | MTOR 4453/4885PIK3CA 4655/4885PIK3CD 4732/4885 |
| US-20110251202-A1 | 1,3-Dihydro-imidazo[4,5-c]quinolin-2-ones as Lipid Kinase Inhibitors | PDPK1, PI4KA, PIP4K2A | MTOR 89/4885PIK3CA 8/4885PIK3CD 9/4885 |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | PDPK1, PI4KA, PIP4K2A | MTOR 89/4885PIK3CA 8/4885PIK3CD 9/4885 |
| US-11999802-B2 | Compositions and methods for selective protein degradation | CRBN, RPS27A, COPB1 | MTOR 3735/4885PIK3CA 3946/4885PIK3CD 3924/4885 |
| US-11981731-B2 | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy | KLRK1, PBK, HAVCR2 | MTOR 4007/4885PIK3CA 1731/4885PIK3CD 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.